Compounds · Other compounds

Why catalogue breadth is not evidence of anything

Compounds › Other compounds research use only needs a source custom synthesis

Under review

Under review. A claim in this topic has been challenged and a moderator has asked for a source. The status is a label, not a judgement, and it is removed when the source arrives or the claim is withdrawn.

c.bakkerTL2 Moderator21 Jan 2026#1

Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below.

I have seen SURPASS-4 (Lancet, 2021) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

9 likes 6mo

k.asanteTL2 Moderator10 May 2026#2

the opening post answers the question as asked. The question underneath it is different.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

0 likes 3mo

VPoulsenTL3Regular26 Jul 2026#3

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

28 likes 2d

Suggested topics

Topic	Participants	Replies	Views	Activity
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…	+100	108	1.3k	8mo
Research-use-only status: what it means legally and practically Compounds › Other compounds research use only custom synthesis needs a source mislabelling Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+72	81	44k	1d
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…	+109	125	2k	16mo
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…	+7	11	5.5k	20mo
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+35	39	688	5mo

Related topics — sharing the tags research use only, needs a source, custom synthesis

Topic	Participants	Replies	Views	Activity
Second pass at: Metformin co-administration and additive GI effects Practice › Interactions hypoglycaemia delayed gastric emptying metformin needs a source On the subject in the title: Second pass at: Metformin co-administration and additive GI effects Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…	+131	142	56k	19d
Citing a preprint in a maintained document: our rule and its reasoning Evidence › Preprints risk of bias effect size needs a source preprint Pinned On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a…		2	467	4mo
Common supplements people ask about, assessed one at a time — a second dataset Practice › Interactions delayed gastric emptying insulin needs a source Posting this under the heading it deserves: Common supplements people ask about, assessed one at a time — a second dataset Everything below is what sits behind that. Reporting something rather than asking…	+97	104	15k	3mo
Documenting a payment dispute without naming and shaming — the long version Sourcing › Payments documentation quality payments research use only Posting this under the heading it deserves: Documenting a payment dispute without naming and shaming — the long version Everything below is what sits behind that. I would like to talk about documentation…		2	32k	1mo
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…	+86	97	62k	8mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →